Beta Drugs Profit & Loss Annual

BSE: - | NSE: BETA | ISIN: INE351Y01019 | Sector: Biotechnology & Drugs

1,845.50 -104.70 (-5.37%)Updated : 12 Oct 2026

Research on

Interim Data

Annual Data

Fiscal Period	2026	2025	2024	2023
Period End Date	Mar 26	Mar 25	Mar 24	Mar 23
Total Operating Expense	326.30	300.26	245.58	184.09
Other Net	1.03	1.08	0.13	-0.04
Diluted Weighted Average Shares	1.01	1.01	1.01	1.01
Depreciation/ Amortization	17.15	12.51	9.78	10.41
Total Extraordinary Items	0.00	-4.57	-	-
Operating Income	58.53	62.09	50.13	43.03
Net Income	41.48	42.42	36.44	30.72
Income Availableto Com Excl Extra Ord	41.48	46.99	36.44	30.72
Other Operating Expenses Total	0.00	-	0.00	0.00
Net Income Before Taxes	54.39	61.54	48.75	41.06
Net Income After Taxes	41.48	46.99	36.44	30.72
Income Availableto Com Incl Extra Ord	41.48	42.42	36.44	30.72
Costof Revenue Total	171.18	211.97	181.20	129.98
Gross Profit	213.65	150.38	114.52	97.13
Interest Inc( Exp) Net- Non- Op Total	-5.16	-1.63	-1.51	-1.93
Diluted Net Income	41.48	42.42	36.44	30.72
Provisionfor Income Taxes	12.91	14.55	12.32	10.34
period Type	-	-	-	-
Net Income Before Extra Items	41.48	46.99	36.44	30.72
Total Revenue	384.83	362.36	295.71	227.11
period Length	12.00	12.00	12.00	12.00
Revenue	384.83	362.36	295.71	227.11
Selling/ General/ Admin Expenses Total	137.97	75.78	54.60	43.69
Diluted Normalized EPS	40.92	46.55	36.10	30.43
Diluted EPS Excluding Extra Ord Items	40.92	46.55	36.10	30.43
Gain( Loss)on Saleof Assets	-	-	0.00	0.00
Unusual Expense( Income)	-	-	0.00	0.00